Hsbc Holdings PLC Makes New $2.16 Million Investment in Medpace Holdings, Inc. $MEDP

Hsbc Holdings PLC purchased a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 3,829 shares of the company’s stock, valued at approximately $2,164,000.

Several other institutional investors have also modified their holdings of the business. Worthington Financial Partners LLC purchased a new stake in shares of Medpace during the fourth quarter worth $1,082,000. Bayban purchased a new position in Medpace in the fourth quarter valued at $44,000. Pacer Advisors Inc. grew its stake in Medpace by 38.1% during the 4th quarter. Pacer Advisors Inc. now owns 153,652 shares of the company’s stock worth $86,299,000 after purchasing an additional 42,362 shares in the last quarter. Virtu Financial LLC grew its stake in Medpace by 83.7% during the 4th quarter. Virtu Financial LLC now owns 1,835 shares of the company’s stock worth $1,031,000 after purchasing an additional 836 shares in the last quarter. Finally, Blue Capital Inc. purchased a new stake in Medpace during the 4th quarter worth about $507,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on MEDP. BMO Capital Markets decreased their price objective on Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a research note on Friday, April 24th. Wall Street Zen lowered shares of Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Robert W. Baird reduced their target price on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Weiss Ratings downgraded shares of Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, April 6th. Finally, Royal Bank Of Canada lowered their price target on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a report on Friday, April 24th. Four investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $467.08.

Medpace Price Performance

Shares of NASDAQ MEDP opened at $534.72 on Tuesday. The company has a market capitalization of $15.27 billion, a price-to-earnings ratio of 33.61, a price-to-earnings-growth ratio of 2.67 and a beta of 1.18. The business has a 50-day moving average of $451.57 and a two-hundred day moving average of $496.59. Medpace Holdings, Inc. has a 1 year low of $306.70 and a 1 year high of $628.92.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The business had revenue of $706.60 million during the quarter, compared to analysts’ expectations of $697.82 million. During the same period in the prior year, the firm posted $3.67 EPS. The business’s quarterly revenue was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, equities research analysts expect that Medpace Holdings, Inc. will post 17.04 earnings per share for the current year.

Insiders Place Their Bets

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the transaction, the general counsel directly owned 20,343 shares of the company’s stock, valued at $9,154,350. This represents a 44.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 20.50% of the stock is currently owned by insiders.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.